AliveCor and OMRON Announce Global Strategic Alliance

AliveCor, a leader in personal ECG products, and OMRON Healthcare, Co., Ltd., a global leader in personal heart health and wellness technology, today announced a global, strategic alliance that combines AliveCor’s ECG technology with industry-leading blood pressure devices from OMRON to better serve customers and expand access to remote patient care.

AliveCor advises this partnership aligns with global trends to deploy non-invasive remote monitoring devices to facilitate patient monitoring while reducing patient and healthcare provider contact during the current pandemic.

“At AliveCor, we are committed to providing life-saving cardiological services to those who need them most. The scope, scale, and strategic importance of this transaction are unprecedented in our corporate history,” said AliveCor CEO Priya Abani. “OMRON’s enormous R&D and distribution resources will bring AliveCor technology to more markets and more end-users than ever before.”

The COVID-19 pandemic underscores the importance of telemedicine in how we care for ourselves and loved ones. Those with chronic illnesses, including heart disease, are at higher risk of infection. AliveCor and OMRON serve this vulnerable population every day by allowing patients to send personal health data to physicians without leaving their homes. The companies’ ability to provide innovative, medical-grade technologies at home offers peace of mind to their users.

“The integration of these complementary technologies allows us to expand the heart health data we provide our customers and physician partners for a more complete picture of a patient’s heart health,” said Isao Ogino, president, and CEO of OMRON Healthcare.  “Our mission is ‘going for zero’ heart attacks and strokes. It is a lofty goal and we have committed to combining forces with like-minded partners to achieve it. OMRON has already made important strides with AliveCor to advance our mission and this expansion of that collaboration, including the development of remote patient monitoring services, is a valuable boost to our growing healthcare portfolio.”

The first technology collaboration between the two companies is the FDA cleared, award-winning OMRON Complete. Introduced in 2019, Complete is the first blood pressure monitor with ECG capability in a single device. The companies expect this product to be the first in a line of integrated ECG and blood pressure devices making home heart care more accessible to consumers than ever before.

The companies also announced today the closing of an equity investment by OMRON Corporation (OMRON Healthcare’s parent company) in AliveCor.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.